MSD Manual

Please confirm that you are a health care professional

Loading

Neuromyelitis Optica Spectrum Disorder (NMOSD)

(Neuromyelitis Optica; Devic Disease)

By

Michael C. Levin

, MD, College of Medicine, University of Saskatchewan

Last full review/revision Dec 2019| Content last modified Dec 2019
Click here for Patient Education

Neuromyelitis optica spectrum disorder is a demyelinating disorder that predominantly affects the eyes and spinal cord but can affect other structures in the central nervous system (CNS) that contain aquaporin 4.

Neuromyelitis optica spectrum disorder causes acute optic neuritis, sometimes bilateral, plus demyelination of the cervical or thoracic spinal cord. It was previously considered to be a variant of multiple sclerosis (MS) but is now recognized as a different disorder.

In neuromyelitis optica spectrum disorder, the immune system targets aquaporin 4, a protein that is present on astrocytes in the brain and particularly the spinal cord and optic nerves, and possibly other targets. Astrocytes are damaged by autoimmune-mediated inflammation as well as demyelination.

Symptoms and Signs

Symptoms of neuromyelitis optica spectrum disorder include visual loss, muscle spasms, paraparesis or quadriparesis, and incontinence.

Specific characteristic presentations include

  • Severe bilateral optic neuritis that involves the optic chiasm, causing loss of vision in the horizontal half of the visual field (altitudinal visual field defect) or loss of acuity (20/200 or worse)

  • A complete spinal cord syndrome, particularly with paroxysmal tonic spasms

  • An area postrema syndrome, causing intractable hiccups or nausea and vomiting (the area postrema is a structure that controls vomiting and is located on the floor of the 4th ventricle)

  • Acute transverse myelitis extending over ≥ 3 contiguous spinal cord segments Neuromyelitis Optica Spectrum Disorder (NMOSD) : Symptoms and signs reference

Symptoms and signs reference

  • 1. Wingerchuk DM, Banwell B, Bennett JL, et al: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 (2):177–189, 2015. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.

Diagnosis

  • Brain and spinal cord MRI

  • Visual evoked potentials

Diagnosis of neuromyelitis optica spectrum disorder usually includes brain and spinal cord MRI and visual evoked potentials.

The following features help distinguish neuromyelitis optica from multiple sclerosis (MS):

  • Neuromyelitis optica affects several (typically ≥ 3) contiguous spinal segments of the spinal cord, whereas MS typically affects a single segment.

  • On MRI, cerebral white matter lesions are uncommon in neuromyelitis optica, unlike in MS.

  • On MRI, morphology and distribution of the lesions differ from those in MS.

Visual evoked potentials can help differentiate neuromyelitis optica from other optic neuropathies. Findings in neuromyelitis optica spectrum disorder include reduced amplitudes or prolonged latencies. This test is also useful for detecting clinically inapparent damage before symptoms develop.

Blood tests to measure an IgG antibody specific for neuromyelitis optica spectrum disorder (aquaporin-4 antibody [also known as NMO-IgG]) may be done to differentiate it from MS. Anti-MOG (myelin oligodendrocyte glycoprotein) antibodies identify a subset of patients who have neuromyelitis optica spectrum disorder and who appear to have different clinical features, fewer exacerbations, and better recovery than patients with aquaporin-4 antibodies or with neither antibody.

Treatment

  • Corticosteroids and immunomodulatory or immunosuppressive treatments

There is no cure for neuromyelitis optica. However, treatment can prevent, slow, or decrease the severity of exacerbations.

Eculizumab, a C5 complement inhibitor, was recently approved for the treatment of antibody-positive neuromyelitis optica spectrum disorder. Adverse effects include respiratory infections, headache, and pneumonia and may be significant; thus, patients should be closely monitored (1).

Methylprednisolone and azathioprine are often used together. Plasma exchange may help people who do not respond to corticosteroids.

Rituximab, an anti–B-cell antibody, reduces IgG production and appears to stabilize the disease. Other immunomodulatory therapies are sometimes used. Natalizumab and fingolimod appear ineffective and may be harmful.

Treatment of symptoms is similar to that for MS. Baclofen or tizanidine may relieve muscle spasms.

Treatment reference

  • 1. Pittock SJ, Berthele A, Fujihara K, et al: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381 (7):614–625, 2019. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.

Key Points

  • Neuromyelitis optica spectrum disorder causes demyelination, typically with antibodies to aquaporin-4 or myelin oligodendrocyte glycoprotein.

  • Typical symptoms include visual loss, muscle spasms, paraparesis or quadriparesis, and incontinence.

  • Diagnose neuromyelitis optica spectrum disorder using brain and spinal cord MRI and visual evoked potentials.

  • Treatments include corticosteroids and immunomodulatory or immunosuppressive treatments (eg, eculizumab, rituximab).

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Overview of Epilepsy
Video
Overview of Epilepsy
3D Models
View All
Vertebra and Spinal Nerve Roots
3D Model
Vertebra and Spinal Nerve Roots

SOCIAL MEDIA

iOS Android
iOS Android
iOS Android
TOP